Status:
COMPLETED
Effect of Dulaglutide on Glycemic Variability in Patients With Type 2 Diabetes
Lead Sponsor:
Shanghai Zhongshan Hospital
Conditions:
Type 2 Diabetes
Eligibility:
All Genders
18-70 years
Brief Summary
Glycemic variability will be assessed using continuous glucose monitor(CGM) in type 2 diabetic patients who receive dulaglutide 1.5 mg/qw injection for 4 weeks.
Detailed Description
Glycemic fluctuation is a major problem in glucose control in diabetic patients. It is interesting to know that whether weekly GLP-1RA can improve glycemic variability in diabetic patients. The presen...
Eligibility Criteria
Inclusion
- Fully understand the test content and possible adverse reactions and voluntarily participate in the trial and sign the informed consent form;
- Meet the World Health Organization(WHO) (1999) criteria for the diagnosis and classification criteria for type 2 diabetes;
- 18 ≤ age ≤ 70 years old, male or female;
Exclusion
- Subjects with Type 1 diabetes mellitus or secondary diabetes mellitus (i.e. any type other than T2DM)
- Personal history or family history of thyroid medullary carcinoma or multiple endocrine neoplasia type 2 (MEN2).
- History of pancreatitis or considered clinically at significant risk of developing pancreatitis during the course of the study (e.g. due to symptomatic gallstones).
- History of significant gastrointestinal (GI) surgery that in the opinion of the investigator is likely to significantly affect upper GI or pancreatic function.
- Fasting triglyceride level more than 750 mg/dL at screening.
- Estimated Glomerular Filtration Rate (eGFR) less than 60 mL/minute/1.73 meter\^2 (calculated using the Schwartz equation) at screening.
- ALT more than 2.5x upper limit of normal (ULN) or Bilirubin more than 1.5xULN (isolated bilirubin more than 1.5xULN is acceptable if bilirubin is fractionated and direct bilirubin more than 35%) at screening.
- Use of a GLP-1receptor agonist at study entry and during the study.
Key Trial Info
Start Date :
May 8 2020
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
June 30 2021
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT04374578
Start Date
May 8 2020
End Date
June 30 2021
Last Update
March 31 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
180 Fenglin Road
Shanghai, China, 200032